AIM ImmunoTech slumps 50% after pricing $8M securities offering
Source: SeekingAlpha
2025-07-29 09:10:13 ET
More on AIM ImmunoTech
- AIM ImmunoTech granted U.S. patent for Ampligen
- AIM Immunotech announces NYSE American removal of trading suspension
- Seeking Alpha’s Quant Rating on AIM ImmunoTech
- Historical earnings data for AIM ImmunoTech
- Financial information for AIM ImmunoTech
Read the full article on Seeking Alpha
For further details see:
AIM ImmunoTech slumps 50% after pricing $8M securities offering
AIM ImmunoTech Inc.
NASDAQ: AIM
AIM Trading
57.55% G/L:
$0.4038 Last:
448,184,778 Volume:
$0.2756 Open:
